|

NTLA-2001 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • Intellia Therapeutics1

Indications

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy1
  • Heart Disease1

Tucson, Arizona1 trial

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

University of Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.